fashion -WSS

fashion

author：Wikipedia 2025-10-01 21:33:17 - browse：83538

Illustration of three connected puzzle pieces, with a woman standing near the missing/empty puzzle piece space. -- first opinion coverage from STAT — Adobe

Women have always been underrepresented in medical research. A new study reveals that not much has changed, especially when it comes to tests of cardiovascular devices.

In a paper published in JAMA Internal Medicine on Monday, researchers found that the percentage of women represented in high-risk medical device trials did not increase from 2010 to 2020. Women generally made up just 33% of participants when the team reviewed 195 trials published from 2016 to 2022. The percentages varied between devices: Women made up 46% of participants in orthopedic trials, but 29% in cardiovascular studies.

The issue isn’t new. The government has made some strides in correcting earlier missteps, like the Food and Drug Administration telling researchers in 1977 to exclude women of reproductive potential from early clinical trials. But stakeholders think agencies like the FDA could do more to incentivize the enrollment of women.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

hotspot

WSS

Patients, doctors are clashing about side effects of hormonal birth control

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Millions may soon lose Medicaid when they don't have to

STAT Readout: Friday, Oct. 20 biotech updates

STAT Summit: Meghan O’Rourke on making chronic illness visible

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roivant's CEO is a star, but biotech's black hole persists

Novavax promises a turnaround & Lilly roils the obesity market

The problems with dementia villages

In Memoriam: Notable people who died in 2023

Can medical device makers keep up in the race to treat obesity?

Medicare details structure of new drug price negotiation program

Xenotransplantation trials will require adjusting expectations, experts say

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The problems with dementia villages

explore

Can medical device makers keep up in the race to treat obesity?

Patients, doctors are clashing about side effects of hormonal birth control

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

focus

hotspot

entertainment

Wikipedia